Clinical outcome of tailored adjuvant postoperative chemoradiotherapy in IB FIGO stage cervical cancer.
OBJECTIVE
The aim of the present report is to review a mono-institutional experience of postoperative radiotherapy in selected patients with cervical cancer.


METHODS
Between 1999 and 2008, fifty-one patients with high-risk stage IB cervical cancer underwent tailored adjuvant postoperative radiotherapy; concurrent chemoradiotherapy was administered to patients presenting a high risk of recurrence. The median follow-up was 58 months.


RESULTS
All patients were in complete remission at first follow-up assessment. Ten patients were subject to recurrences between 7 and 54 months after treatment. The 2-year and 5-year disease-free survival rates were 88.1% and 74.9%, respectively; 2-year and 5-year overall survival rates of the whole group were 91.8% and 82.0%, respectively. Only one case of grade 4 and four cases of grade 3 side effects were reported.


CONCLUSIONS
Tailored adjuvant postoperative chemoradiotherapy is able to obtain a satisfactory clinical outcome in patients with high-risk early-stage IB cervical cancer.
Radiotherapy Division, Pisa University Hospital, Italy.
Maria Grazia
MG
Fabrini
Angiolo
A
Gadducci
Franco
F
Perrone
Stefania
S
Cosio
Concetta
C
Laliscia
Francesco
F
Pasqualetti
Silvia
S
Grespi
Luca
L
Cionini
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011182:Postoperative Care; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery